## **Core Concept**
Bezlotoxumab is a monoclonal antibody used to prevent a specific complication in patients. It targets a toxin produced by certain bacteria, thereby preventing infection.

## **Why the Correct Answer is Right**
Bezlotoxumab is specifically designed to prevent *Clostridioides difficile* (C. difficile) infection in adults who are at a high risk for recurrence and are receiving antibiotics for *C. difficile* infection. It works by binding to toxin B of *C. difficile*, preventing the toxin from causing damage to the intestinal lining. This mechanism helps in reducing the recurrence of *C. difficile* infection.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because bezlotoxumab is not primarily used for autoimmune diseases; it is targeted for infectious disease prevention.
- **Option B:** This option is incorrect because bezlotoxumab does not work by enhancing the effect of antibiotics; rather, it directly neutralizes bacterial toxins.
- **Option C:** This option might seem plausible but is incorrect because bezlotoxumab's use is more specific to preventing *C. difficile* recurrence rather than broadly treating bacterial infections.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that bezlotoxumab is administered as a single dose intravenously and is specifically indicated for adults with *C. difficile* infection who are at a high risk of recurrence. It represents a targeted approach to preventing *C. difficile* recurrence, distinct from general treatments for *C. difficile* infection.

## **Correct Answer:** D. Prevention of *Clostridioides difficile* infection recurrence.